Carcinoembryonic antigen (CEA) is a glycoprotein whose serum concentration is often elevated in cancers of the gastrointestinal tract, breast, lung and in gynecological malignancies (Tuxen et al. 1999). CEA is elevated in approximately 34–37% of the patients with ovarian cancer and more often in mucinous (88%) than in non-mucinous (19%) cancers (Bast et al. 1984, Tholander et al. 1990, Stenman et al. 1995, Tuxen et al. 1995). Serial CEA determinations can be used to predict prognosis in ovarian cancer. Declining or persistently low CEA levels are associated with a better prognosis than high or rising levels. Thus, for mucinous ovarain cancer, as a unique type of ovarain cancer, CEA monitoring is reasonable.
Tumor Markers: Physiology, Pathobiology, Technology, and Clinical Applications By Eleftherios P. Diamandis5, 41 pages